SLC5A2 and hydrops fetalis: To this date, empagliflozin is also the first among SGLT2-inhibitors to show beneficial effects in all HF subtypes since the results of the The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved trial) were published.